Current Report Filing (8-k)
16 May 2023 - 6:10AM
Edgar (US Regulatory)
0001557376
false
0001557376
2023-05-12
2023-05-12
iso4217:USD
xbrli:shares
iso4217:USD
xbrli:shares
UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
WASHINGTON,
D.C. 20549
FORM
8-K
Pursuant
to Section 13 or 15(d) of The Securities Exchange Act of 1934
Date
of report (Date of earliest event reported): May 12, 2023
ORGANICELL
REGENERATIVE MEDICINE, INC.
(Exact
name of registrant as specified in its charter)
Nevada |
|
000-55008 |
|
47-4180540 |
(State or Other Jurisdiction
of Incorporation) |
|
(Commission File Number) |
|
(IRS Employer
Identification No.) |
3321
College Avenue, Suite 246
Davie,
Florida |
|
33314 |
(Address of Principal Executive
Offices) |
|
(Zip Code) |
Registrant’s
telephone number, including area code: (888) 963-7881
(Former
name or former address, if changed since last report)
Check
the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under
any of the following provisions (see General Instruction A.2. below):
☐ |
Written communications
pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
☐ |
Soliciting material pursuant
to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
☐ |
Pre-commencement communications
pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
☐ |
Pre-commencement communications
pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Securities
registered pursuant to Section 12(b) of the Act:
Title
of each Class |
|
Trading
Symbol |
|
Name
of each exchange on which registered |
None |
|
N/A |
|
N/A |
Indicate
by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405
of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging
growth company ☐
If
an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying
with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
As
used in this Current Report on Form 8-K (this “Report”), and unless otherwise indicated, the terms “the Company,”
“Organicell,” “we,” “us” and “our” refer to Organicell Regenerative
Medicine, Inc., and its subsidiaries.
Item 5.02 |
Departure of Directors
or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. |
On
May 12, 2023, Organicell terminated Albert Mitrani as its Executive Vice President of Sales and contemporaneously terminated his employment
agreement with the Company.
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by
the undersigned hereunto duly authorized.
Dated: May 15, 2023 |
ORGANICELL REGENERATIVE MEDICINE, INC. |
|
|
|
By: |
/s/
Ian Bothwell |
|
|
Ian Bothwell
Chief Financial Officer |
Organicell Regenerative ... (QB) (USOTC:OCEL)
Historical Stock Chart
From Apr 2024 to May 2024
Organicell Regenerative ... (QB) (USOTC:OCEL)
Historical Stock Chart
From May 2023 to May 2024